Caudill Cortney 4

What Happened Cortney Caudill, Chief Operating Officer of Halozyme Therapeutics (HALO), was granted four derivative equity awards on February 9, 2026 totaling 44,248 units (14,047; 13,047; 2,403; 14,751). Each grant is reported at $0.00 (derivative awards/awarded stock units), meaning no cash was paid at grant; the awards are subject to vesting and/or performance conditions described in the filing. This is an award/grant (not a purchase or sale) and does not by itself signal an immediate market transaction.

Key Details

• Transaction date: 2026-02-09; reported on Form 4 filed 2026-02-11 (timely filing).
• Grants reported (all "A" = award/acquisition, derivative, $0.00): 14,047; 13,047; 2,403; 14,751 — total 44,248 units.
• Shares owned after the transaction: not disclosed in the excerpt provided (check the full Form 4 for total holdings).
• Notable footnotes from the filing:
  • F1: An option award with vesting of one-fourth on the indicated date and then 1/48th monthly thereafter.
  • F2: A time-based award vesting one-fourth on the first anniversary, then one-fourth on each subsequent anniversary.
  • F3: PSUs from 2/23/2024 — the listed units reflect the number that became eligible to vest based on performance for the period ending 12/31/2025; units remain subject to a service requirement through the third anniversary of the PSU grant date.
  • F4: PSUs from 2/20/2025 — similarly, these reflect performance-determined units for period ending 12/31/2025 and remain subject to a service-based vesting requirement through the third anniversary of the grant.
• Filing timeliness: Form 4 was filed within the standard SEC two-business-day window (transaction 2/9/2026, filed 2/11/2026).

Context These entries are derivative equity awards (stock options, time-based RSUs, and performance-based RSUs/PSUs) and generally represent future economic interest contingent on vesting or achievement of performance goals and service requirements. They are not cash purchases or sales and do not indicate immediate buying/selling activity. For full details on total holdings, exact vesting dates, and potential future dilution or realized value, consult the complete Form 4 filing and Halozyme’s grant agreements.